Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond MM Hupperts, Cavit Boz Show all
Neurology Clinical Practice | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016
Awarded by NHMRC
Awarded by NHMRC Center for Research Excellence
Awarded by Czech Ministry of Education
Supported by the NHMRC Career Development Award (Clinical) to H.B. (ID628856), NHMRC Early Career Fellowship (1071124), NHMRC Project Grants (1032484 and 1083539), NHMRC Center for Research Excellence (Grant ID 1001216), and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen, Novartis Pharma, Bayer-Schering, Sanofi-Aventis, and BioCSL. The Tysabri Observational Program is fully funded by Biogen. E. Havrdova and D. Horakova have been supported by Research Grant of Czech Ministry of Education, PRVOUK-P26/LF1/4.